ArticleCancer immunology, immunotherapy : CII2024

New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo.

Iga Jancewicz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.